Yvette Drew

Framlington Place
Newcastle Upon Tyne, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Interpreting homologous recombination deficiency in rare gynecological cancers: A case of primary mucinous endometrial adenocarcinoma of gastrointestinal type.

Interpreting homologous recombination deficiency in rare gynecological cancers: A case of primary mucinous endometrial adenocarcinoma of gastrointestinal type.

Journal: Gynecologic oncology reports

Published: June 23, 2026

Exploring novel therapeutic targets in vulvar squamous cell carcinoma.

Exploring novel therapeutic targets in vulvar squamous cell carcinoma.

Journal: Gynecologic oncology

Published: October 03, 2025

Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

Journal: British journal of cancer

Published: September 20, 2025

Bridging historical evidence and contemporary strategies in the adjuvant treatment of early-stage epithelial ovarian cancer.

Bridging historical evidence and contemporary strategies in the adjuvant treatment of early-stage epithelial ovarian cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: August 08, 2025

Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review.

Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review.

Journal: Gynecologic oncology

Published: August 03, 2025

Clearing the Path for Immunologic Targeting of Gynecologic Clear Cell Carcinomas.

Clearing the Path for Immunologic Targeting of Gynecologic Clear Cell Carcinomas.

Journal: JAMA oncology

Published: July 03, 2025

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications.

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications.

Journal: Nature reviews. Drug discovery

Published: September 17, 2024

A Systematic Review of the Molecular Mechanisms Involved in the Association Between PCOS and Endometrial and Ovarian Cancers.

A Systematic Review of the Molecular Mechanisms Involved in the Association Between PCOS and Endometrial and Ovarian Cancers.

Journal: Journal of cellular and molecular medicine

Published: June 18, 2024

Trop2 Expression in Correlation to the Molecular Subtype in Vulvar Squamous Cell Carcinomas.

Trop2 Expression in Correlation to the Molecular Subtype in Vulvar Squamous Cell Carcinomas.

Journal: Pathobiology : journal of immunopathology, molecular and cellular biology

Published: June 17, 2024

Challenges in PARP inhibitor therapy: A case of Olaparib-induced liver injury and successful rechallenge with Niraparib.

Challenges in PARP inhibitor therapy: A case of Olaparib-induced liver injury and successful rechallenge with Niraparib.

Journal: Gynecologic oncology reports

Published: June 04, 2024

Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers.

Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 24, 2023

Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.

Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 30, 2023

Showing 1-12 of 49

Last Updated: 09/26/2026